Nifty
Sensex
:
:
18538.30
62387.45
25.55 (0.14%)
93.81 (0.15%)

Pharmaceuticals & Drugs - Global

Rating :
42/99

BSE: 532523 | NSE: BIOCON

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 33,880.93
  • 54.91
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 37,037.43
  • 0.18%
  • 3.52

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 60.64%
  • 0.97%
  • 12.07%
  • FII
  • DII
  • Others
  • 15.79%
  • 7.76%
  • 2.77%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 12.66
  • 14.69
  • 9.11

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.73
  • 12.50
  • 3.51

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.33
  • 19.49
  • 3.25

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 45.85
  • 63.04
  • 63.62

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.07
  • 6.02
  • 5.89

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 22.25
  • 26.20
  • 24.08

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 22
Sep 21
Var%
Jun 22
Jun 21
Var%
Mar 22
Mar 21
Var%
Dec 21
Dec 20
Var%
Net Sales
2,319.70
1,840.40
26.04%
2,139.50
1,760.60
21.52%
2,408.80
1,842.10
30.76%
2,174.20
1,857.40
17.06%
Expenses
1,849.00
1,394.60
32.58%
1,740.10
1,371.30
26.89%
1,816.90
1,406.40
29.19%
1,686.00
1,457.60
15.67%
EBITDA
470.70
445.80
5.59%
399.40
389.30
2.59%
591.90
435.70
35.85%
488.20
399.80
22.11%
EBIDTM
20.29%
24.22%
18.67%
22.11%
24.57%
23.65%
22.45%
21.52%
Other Income
64.50
104.90
-38.51%
77.90
47.20
65.04%
67.30
205.40
-67.23%
48.30
27.90
73.12%
Interest
30.00
22.50
33.33%
19.90
19.90
0.00%
10.50
33.90
-69.03%
14.70
4.80
206.25%
Depreciation
230.80
201.50
14.54%
217.50
194.80
11.65%
212.20
184.30
15.14%
205.70
186.30
10.41%
PBT
257.40
256.60
0.31%
239.90
221.80
8.16%
395.50
435.50
-9.18%
316.10
236.60
33.60%
Tax
147.30
46.30
218.14%
29.50
57.30
-48.52%
58.60
69.40
-15.56%
49.30
48.90
0.82%
PAT
110.10
210.30
-47.65%
210.40
164.50
27.90%
336.90
366.10
-7.98%
266.80
187.70
42.14%
PATM
4.75%
11.43%
9.83%
9.34%
13.99%
19.87%
12.27%
10.11%
EPS
0.39
1.15
-66.09%
1.20
0.70
71.43%
1.99
2.11
-5.69%
1.56
1.41
10.64%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Net Sales
9,042.20
8,184.00
7,143.10
6,300.50
5,514.40
4,123.40
3,891.10
3,347.40
3,089.80
2,877.30
2,485.30
Net Sales Growth
23.86%
14.57%
13.37%
14.26%
33.73%
5.97%
16.24%
8.34%
7.39%
15.77%
 
Cost Of Goods Sold
2,995.90
2,718.40
2,243.70
1,989.50
1,896.60
1,636.10
1,446.60
1,290.40
1,255.60
1,186.10
1,044.40
Gross Profit
6,046.30
5,465.60
4,899.40
4,311.00
3,617.80
2,487.30
2,444.50
2,057.00
1,834.20
1,691.20
1,440.90
GP Margin
66.87%
66.78%
68.59%
68.42%
65.61%
60.32%
62.82%
61.45%
59.36%
58.78%
57.98%
Total Expenditure
7,092.00
6,690.20
5,841.00
5,043.50
4,390.60
3,294.30
2,911.60
2,584.30
2,394.00
2,190.20
1,946.30
Power & Fuel Cost
-
316.40
270.30
246.10
239.80
189.00
156.40
184.70
176.70
162.40
142.60
% Of Sales
-
3.87%
3.78%
3.91%
4.35%
4.58%
4.02%
5.52%
5.72%
5.64%
5.74%
Employee Cost
-
1,880.10
1,741.00
1,458.80
1,165.30
931.10
747.00
610.10
533.40
466.30
389.40
% Of Sales
-
22.97%
24.37%
23.15%
21.13%
22.58%
19.20%
18.23%
17.26%
16.21%
15.67%
Manufacturing Exp.
-
1,243.50
1,019.20
864.60
721.20
335.70
391.50
203.70
81.20
62.90
95.20
% Of Sales
-
15.19%
14.27%
13.72%
13.08%
8.14%
10.06%
6.09%
2.63%
2.19%
3.83%
General & Admin Exp.
-
181.50
270.50
182.10
53.00
56.80
21.70
144.60
165.70
131.80
122.20
% Of Sales
-
2.22%
3.79%
2.89%
0.96%
1.38%
0.56%
4.32%
5.36%
4.58%
4.92%
Selling & Distn. Exp.
-
243.80
235.90
266.30
277.50
98.20
107.40
100.80
108.70
118.90
99.60
% Of Sales
-
2.98%
3.30%
4.23%
5.03%
2.38%
2.76%
3.01%
3.52%
4.13%
4.01%
Miscellaneous Exp.
-
106.50
60.40
36.10
37.20
47.40
41.00
50.00
72.70
61.80
99.60
% Of Sales
-
1.30%
0.85%
0.57%
0.67%
1.15%
1.05%
1.49%
2.35%
2.15%
2.13%
EBITDA
1,950.20
1,493.80
1,302.10
1,257.00
1,123.80
829.10
979.50
763.10
695.80
687.10
539.00
EBITDA Margin
21.57%
18.25%
18.23%
19.95%
20.38%
20.11%
25.17%
22.80%
22.52%
23.88%
21.69%
Other Income
258.00
689.10
605.20
507.50
414.30
206.20
157.10
83.90
53.10
55.90
56.70
Interest
75.10
67.60
57.70
64.90
70.90
61.50
26.00
29.30
8.90
1.70
8.10
Depreciation
866.20
814.20
715.10
552.20
447.80
385.10
277.20
248.70
221.00
203.60
179.30
PBT
1,208.90
1,301.10
1,134.50
1,147.40
1,019.40
588.70
833.40
569.00
519.00
537.70
408.30
Tax
284.70
211.50
221.50
315.10
212.30
156.90
161.60
142.20
95.70
106.90
97.50
Tax Rate
23.55%
17.77%
19.31%
25.94%
17.49%
26.65%
19.39%
19.49%
15.33%
19.88%
15.98%
PAT
924.20
855.30
819.90
777.10
904.40
351.10
595.80
528.70
497.40
413.80
508.90
PAT before Minority Interest
788.50
978.50
925.60
899.80
1,001.70
431.80
671.80
587.40
528.40
430.80
512.70
Minority Interest
-135.70
-123.20
-105.70
-122.70
-97.30
-80.70
-76.00
-58.70
-31.00
-17.00
-3.80
PAT Margin
10.22%
10.45%
11.48%
12.33%
16.40%
8.51%
15.31%
15.79%
16.10%
14.38%
20.48%
PAT Growth
-0.47%
4.32%
5.51%
-14.08%
157.59%
-41.07%
12.69%
6.29%
20.20%
-18.69%
 
EPS
7.70
7.12
6.83
6.47
7.53
2.92
4.96
4.40
4.14
3.45
4.24

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Shareholder's Funds
8,432.50
7,626.90
6,705.80
6,098.00
5,180.80
4,837.70
4,033.80
3,270.60
3,026.70
2,694.60
Share Capital
600.30
600.00
600.00
300.00
300.00
100.00
100.00
100.00
100.00
100.00
Total Reserves
7,628.10
6,872.80
5,997.00
5,720.80
4,812.30
4,670.20
3,873.00
3,132.70
2,806.20
2,491.80
Non-Current Liabilities
6,802.70
5,496.90
2,684.70
2,122.30
2,006.50
2,304.60
2,421.30
1,377.90
1,262.00
666.30
Secured Loans
2,574.30
1,492.40
1,220.80
1,523.50
1,787.00
2,104.30
2,061.00
758.20
580.40
124.00
Unsecured Loans
1,424.20
1,469.20
1.40
2.10
2.80
3.90
11.40
11.40
25.80
40.00
Long Term Provisions
91.70
106.20
85.80
66.10
49.30
36.00
29.90
15.00
7.80
4.00
Current Liabilities
3,828.00
4,210.10
4,008.00
3,038.50
2,141.30
1,678.30
1,665.70
1,554.70
1,379.60
989.90
Trade Payables
1,608.50
1,513.90
1,325.10
1,198.30
1,005.30
739.70
609.80
429.30
347.20
345.50
Other Current Liabilities
1,031.20
1,840.20
1,784.40
1,374.70
870.10
698.20
527.10
706.20
612.30
313.10
Short Term Borrowings
896.00
594.20
667.60
261.20
130.30
97.20
394.90
261.00
243.50
84.80
Short Term Provisions
292.30
261.80
230.90
204.30
135.60
143.20
133.90
158.20
176.60
246.50
Total Liabilities
20,100.70
18,214.60
14,075.80
11,867.70
9,796.30
9,196.70
8,386.60
6,375.40
5,750.60
4,416.10
Net Block
6,569.00
6,363.90
5,971.10
4,471.00
3,699.50
3,625.10
1,748.30
1,629.90
1,525.20
1,510.30
Gross Block
11,233.00
10,220.90
9,147.40
7,095.00
5,873.80
5,436.10
3,403.60
3,034.20
2,701.70
2,480.90
Accumulated Depreciation
4,664.00
3,857.00
3,176.30
2,624.00
2,174.30
1,811.00
1,655.30
1,404.30
1,176.50
970.60
Non Current Assets
11,718.40
10,614.20
8,750.80
6,979.20
5,647.70
5,149.00
4,415.70
3,812.80
3,111.80
2,176.10
Capital Work in Progress
4,110.40
2,800.20
2,196.00
1,898.90
1,302.80
839.20
2,239.50
1,676.40
1,205.60
312.50
Non Current Investment
370.20
743.20
108.50
182.50
63.80
188.80
26.80
0.00
64.50
64.50
Long Term Loans & Adv.
483.80
436.40
402.00
335.80
437.20
319.70
350.10
336.90
252.00
241.60
Other Non Current Assets
185.00
270.50
73.20
91.00
144.40
176.20
51.00
169.60
64.50
47.20
Current Assets
8,382.30
7,600.40
5,325.00
4,888.50
4,148.60
4,047.70
3,970.90
2,562.60
2,638.80
2,240.00
Current Investments
1,217.70
1,208.70
857.60
829.30
611.40
1,065.00
874.70
230.30
700.40
522.10
Inventories
2,298.20
1,866.60
1,435.90
1,031.60
722.50
635.30
542.40
452.70
376.60
398.40
Sundry Debtors
2,058.20
1,503.30
1,223.70
1,291.80
1,063.90
883.20
714.50
770.50
599.80
509.70
Cash & Bank
1,747.50
2,015.40
998.60
1,057.20
1,322.80
1,044.30
1,538.60
937.50
804.40
672.90
Other Current Assets
1,060.70
713.10
543.60
525.50
428.00
419.90
300.70
171.60
157.60
136.90
Short Term Loans & Adv.
400.50
293.30
265.60
153.10
54.70
24.10
134.70
75.80
81.80
81.40
Net Current Assets
4,554.30
3,390.30
1,317.00
1,850.00
2,007.30
2,369.40
2,305.20
1,007.90
1,259.20
1,250.10
Total Assets
20,100.70
18,214.60
14,075.80
11,867.70
9,796.30
9,196.70
8,386.60
6,375.40
5,750.60
4,416.10

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Cash From Operating Activity
1,176.60
1,159.70
1,283.10
1,154.60
662.10
640.00
370.60
210.70
560.70
471.20
PBT
983.10
1,067.70
870.90
1,002.60
610.00
849.70
751.30
624.10
537.70
610.20
Adjustment
1,245.00
709.60
921.40
472.60
355.70
204.40
42.00
74.00
134.00
147.30
Changes in Working Capital
-789.50
-423.80
-165.10
-29.10
-106.50
-211.10
-176.20
-354.00
37.70
-192.30
Cash after chg. in Working capital
1,438.60
1,353.50
1,627.20
1,446.10
859.20
843.00
617.10
344.10
709.40
565.20
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-262.00
-193.80
-344.10
-291.50
-197.10
-203.00
-246.50
-133.40
-148.70
-94.00
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,699.10
-3,624.70
-1,558.90
-713.80
-684.00
-498.50
-1,141.70
-508.70
-938.10
-375.80
Net Fixed Assets
-284.70
-130.90
744.40
-280.60
-177.90
-215.90
-216.90
-57.90
-322.80
-213.80
Net Investments
136.70
-456.90
-890.30
107.80
-310.70
-79.30
-3,688.10
328.50
125.80
38.00
Others
-1,551.10
-3,036.90
-1,413.00
-541.00
-195.40
-203.30
2,763.30
-779.30
-741.10
-200.00
Cash from Financing Activity
242.10
2,564.00
387.60
-241.70
-239.70
-177.50
1,067.60
186.20
426.00
-8.60
Net Cash Inflow / Outflow
-280.40
99.00
111.80
199.10
-261.60
-36.00
296.50
-111.80
48.60
86.80
Opening Cash & Equivalents
897.00
824.70
659.30
449.00
710.20
757.50
457.50
557.00
474.00
369.00
Closing Cash & Equivalent
653.70
897.00
824.70
659.30
449.00
710.20
757.50
462.60
557.00
474.00

Financial Ratios

Consolidated /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Book Value (Rs.)
68.53
62.27
54.97
50.17
42.59
39.74
33.10
26.93
24.21
21.59
ROA
5.11%
5.73%
6.94%
9.25%
4.55%
7.64%
7.96%
8.72%
8.47%
12.28%
ROE
12.47%
13.16%
14.26%
18.00%
8.74%
15.37%
16.31%
17.22%
15.68%
21.50%
ROCE
9.93%
11.30%
14.35%
16.11%
8.92%
12.59%
13.93%
15.30%
15.75%
22.47%
Fixed Asset Turnover
0.76
0.74
0.78
0.85
0.73
0.89
1.05
1.09
1.12
1.11
Receivable days
79.42
69.67
72.86
77.96
86.05
74.35
80.16
80.09
69.48
72.22
Inventory Days
92.87
84.38
71.47
58.05
60.00
54.81
53.71
48.47
48.54
56.01
Payable days
209.62
230.92
81.60
81.98
87.98
78.68
71.28
58.15
55.73
65.24
Cash Conversion Cycle
-37.33
-76.87
62.74
54.04
58.07
50.48
62.59
70.42
62.29
62.99
Total Debt/Equity
0.60
0.58
0.40
0.40
0.44
0.48
0.62
0.35
0.30
0.10
Interest Cover
18.60
20.88
19.72
18.12
10.57
33.05
25.90
71.12
317.29
76.33

News Update:


  • Biocon raises Rs 2,250 crore through Commercial Papers
    24th Nov 2022, 10:29 AM

    Date of maturity of said Commercial Papers will be February 22, 2023

    Read More
  • Biocon signs semi-exclusive partnership agreement with Zentiva
    24th Nov 2022, 09:24 AM

    Under the terms of this agreement Biocon will be responsible for the manufacturing and supply of Liraglutide to Zentiva, for its commercialization across 30 countries in Europe

    Read More
  • Biocon’s arm executes debt facility agreement
    22nd Nov 2022, 16:22 PM

    Debt facility agreement which is classified as a Sustainability-linked Loan amounting to $1.2 billion on November 20, 2022

    Read More
  • Biocon reports 49% fall in Q2 consolidated net profit
    15th Nov 2022, 14:22 PM

    Total consolidated income of the company increased by 22.56% at Rs 2384.20 crore for Q2FY23

    Read More
  • Biocon’s arm featured on the prestigious Asia IP ELITE list for 2022 by lAM
    11th Nov 2022, 12:46 PM

    Biocon was the first and only pharmaceutical company from India to be featured on the ASIA IP ELITE list in 2016

    Read More
  • Biocon named among Top 10 employers in global biotech, pharma and biopharma sector
    31st Oct 2022, 17:46 PM

    Biocon has been ranked 8th on the list this year for three key attributes: ‘innovative leader in the industry’, ‘is socially responsible’ and ‘has loyal employees

    Read More
  • Biocon’s arm enters into strategic out-licensing agreement with Yoshindo
    17th Oct 2022, 09:29 AM

    Under the terms of this deal, Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics

    Read More
  • EDQM conducts GMP inspection at Biocon’s Bangalore unit
    7th Oct 2022, 10:59 AM

    There were no critical deficiencies and one deficiency cited under the category ‘Major’

    Read More
  • Biocon divests 5.4% stake in Syngene International
    7th Sep 2022, 10:11 AM

    The company has sold a total of 21,789,164 shares, at an average price of Rs 560.04 apiece, in Syngene International

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.